Related Experiment Video
Updated: Jun 13, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Effect of impaza on cardiovascular system
A L Markel'1, E S Zhavbert, S A Tarasov
1Institute of Cytology and Genetics, Siberian Division of Russian Academy of Sciences, Novosibirsk.
Bulletin of Experimental Biology and Medicine
|April 17, 2010
Summary
Antibodies to endothelial NO synthase, known as impaza, demonstrated a mild antihypertensive effect in rats, performing slightly less effectively than losartan. Impaza shows promise for treating erectile dysfunction and cardiovascular conditions.
Area of Science:
- Cardiovascular Pharmacology
- Immunology
- Endocrinology
Background:
- Endothelial NO synthase (eNOS) plays a crucial role in regulating vascular tone and blood pressure.
- Erectile dysfunction and cardiovascular pathologies often coexist, indicating shared underlying mechanisms.
- Novel therapeutic approaches targeting eNOS are being investigated for cardiovascular and sexual health.
Purpose of the Study:
- To evaluate the antihypertensive effects of impaza, an antibody to eNOS, in a rat model.
- To compare the efficacy of impaza with a standard antihypertensive drug, losartan.
- To assess the potential of impaza in managing conditions associated with cardiovascular pathology.
Main Methods:
- An experimental study was conducted on ISIAH rats, a model with genetic hypertension.
- Rats were treated with ultralow doses of impaza, antibodies to endothelial NO synthase.
- Blood pressure was monitored to assess the antihypertensive effect.
- A comparative analysis was performed against losartan treatment.
Main Results:
- Impaza administration resulted in a mild and progressive reduction in blood pressure.
- The antihypertensive effect of impaza was found to be slightly inferior to that of losartan.
- No significant adverse effects were reported during the study period.
Conclusions:
- Antibodies to endothelial NO synthase (impaza) exhibit a modest antihypertensive effect in ISIAH rats.
- Impaza represents a potential therapeutic agent for patients with erectile dysfunction and co-existing cardiovascular pathology.
- Further research is warranted to elucidate the full clinical potential of impaza in managing hypertension and related disorders.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...